NCT04146571 2022-10-20Expanded Access to Ensartinib for Participants With ALK+ NSCLCXcovery Holdings, Inc.Available
NCT02784158 2018-02-06An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung CancerTakedaNo longer available